JP2023520205A5 - - Google Patents

Info

Publication number
JP2023520205A5
JP2023520205A5 JP2022559575A JP2022559575A JP2023520205A5 JP 2023520205 A5 JP2023520205 A5 JP 2023520205A5 JP 2022559575 A JP2022559575 A JP 2022559575A JP 2022559575 A JP2022559575 A JP 2022559575A JP 2023520205 A5 JP2023520205 A5 JP 2023520205A5
Authority
JP
Japan
Prior art keywords
immune cells
effector immune
mhc class
effector
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022559575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520205A (ja
Filing date
Publication date
Priority claimed from GBGB2005216.3A external-priority patent/GB202005216D0/en
Application filed filed Critical
Publication of JP2023520205A publication Critical patent/JP2023520205A/ja
Publication of JP2023520205A5 publication Critical patent/JP2023520205A5/ja
Priority to JP2025076879A priority Critical patent/JP2025107358A/ja
Priority to JP2025082745A priority patent/JP2025122064A/ja
Pending legal-status Critical Current

Links

JP2022559575A 2020-04-08 2021-04-08 細胞 Pending JP2023520205A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025076879A JP2025107358A (ja) 2020-04-08 2025-05-02 細胞
JP2025082745A JP2025122064A (ja) 2020-04-08 2025-05-16 細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2005216.3 2020-04-08
GBGB2005216.3A GB202005216D0 (en) 2020-04-08 2020-04-08 Cell
PCT/GB2021/050862 WO2021205172A1 (en) 2020-04-08 2021-04-08 Cell

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025076879A Division JP2025107358A (ja) 2020-04-08 2025-05-02 細胞

Publications (2)

Publication Number Publication Date
JP2023520205A JP2023520205A (ja) 2023-05-16
JP2023520205A5 true JP2023520205A5 (cg-RX-API-DMAC7.html) 2024-02-21

Family

ID=70768915

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022559575A Pending JP2023520205A (ja) 2020-04-08 2021-04-08 細胞
JP2025076879A Pending JP2025107358A (ja) 2020-04-08 2025-05-02 細胞
JP2025082745A Pending JP2025122064A (ja) 2020-04-08 2025-05-16 細胞

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025076879A Pending JP2025107358A (ja) 2020-04-08 2025-05-02 細胞
JP2025082745A Pending JP2025122064A (ja) 2020-04-08 2025-05-16 細胞

Country Status (8)

Country Link
US (3) US20230338534A1 (cg-RX-API-DMAC7.html)
EP (2) EP4132566A1 (cg-RX-API-DMAC7.html)
JP (3) JP2023520205A (cg-RX-API-DMAC7.html)
CN (1) CN115348869A (cg-RX-API-DMAC7.html)
AU (1) AU2021251459A1 (cg-RX-API-DMAC7.html)
CA (1) CA3174659A1 (cg-RX-API-DMAC7.html)
GB (1) GB202005216D0 (cg-RX-API-DMAC7.html)
WO (2) WO2021205173A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
CN117511882A (zh) * 2022-08-03 2024-02-06 浙江大学医学院附属第一医院 一种通用型免疫效应细胞及其制备方法和应用
CN115747166B (zh) * 2022-10-13 2024-12-06 上海怡豪生物科技有限公司 一种通用型car-t细胞及其制备方法与应用
EP4608856A1 (en) * 2022-10-27 2025-09-03 CARGO Therapeutics, Inc. Compositions and methods for improved immunotherapies
JP2026525671A (ja) * 2023-07-26 2026-07-31 ビーアールエル メディシン (シャンハイ) カンパニー リミテッド 疾患を治療するための方法及び組成物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
JP2002541845A (ja) 1999-04-16 2002-12-10 セルテック セラピューティックス リミテッド 合成膜貫通成分
EP1667717A2 (en) 2003-09-09 2006-06-14 GPC Biotech AG Therapeutic human anti-mhc class ii antibodies and their uses
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
RU2744046C2 (ru) 2014-03-05 2021-03-02 Отолус Лимитед ХИМЕРНЫЙ АНТИГЕННЫЙ РЕЦЕПТОР (CAR) С АНТИГЕНСВЯЗЫВАЮЩИМИ ДОМЕНАМИ К КОНСТАНТНОЙ ОБЛАСТИ β Т-КЛЕТОЧНОГО РЕЦЕПТОРА
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
BR112017000939A2 (pt) * 2014-07-21 2017-11-14 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico de cll-1
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
TWI700298B (zh) * 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向b細胞成熟抗原之嵌合型抗原受體類
WO2018170506A1 (en) * 2017-03-17 2018-09-20 University Of Tennessee Research Foundation Methods of using cytotoxic t cells for treatment of autoimmune diseases
GB201709203D0 (en) 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
CN111315769A (zh) * 2017-09-06 2020-06-19 加州理工学院 信号传导和抗原呈递双功能受体(sabr)
GB201716728D0 (en) * 2017-10-12 2017-11-29 Autolus Ltd Cell
CA3082204A1 (en) * 2017-12-13 2019-06-20 Janssen Biotech, Inc. Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression
WO2019210280A1 (en) * 2018-04-27 2019-10-31 Casebia Therapeutics Limited Liability Partnership Anti-bcma car-t-cells for plasma cell depletion
WO2019210281A1 (en) * 2018-04-27 2019-10-31 Casebia Therapeutics Limited Liability Partnership Methods and compositions of cytotoxic t cell depletion
WO2019220109A1 (en) 2018-05-15 2019-11-21 Autolus Limited Chimeric antigen receptor
SG11202102781UA (en) 2018-09-27 2021-04-29 Autolus Ltd Chimeric antigen receptor
GB201817822D0 (en) 2018-10-31 2018-12-19 Autolus Ltd Binding domain
EP3947647A4 (en) * 2019-03-29 2023-01-04 Board of Regents, The University of Texas System METHODS OF MANUFACTURE OF CAR NK CELLS AND USE THEREOF

Similar Documents

Publication Publication Date Title
US20220281944A1 (en) Spycatcher and spytag: universal immune receptors for t cells
Govers et al. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing
US12161668B2 (en) T cells expressing a chimeric antigen receptor
JP7566628B2 (ja) キメラ抗原受容体を発現する免疫細胞
US20170342124A1 (en) Universal Immune Receptor Expressed by T Cells for the Targeting of Diverse and Multiple Antigens
JP2023506184A (ja) Lilrb1ベースのキメラ抗原受容体
CA3125345A1 (en) Anti-tcr antibody molecules and uses thereof
JP2019525771A5 (cg-RX-API-DMAC7.html)
IL277398B2 (en) Pd-l1 binding affimers, and uses related thereto
JP2021529559A (ja) グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用
JP7723420B2 (ja) B細胞標的化並列CAR(pCAR)治療的薬剤
CN108513576A (zh) 可调变体免疫球蛋白超家族结构域和工程改造的细胞治疗
CA3002751A1 (en) Methods for culturing cells and kits and apparatus for same
RU2018109426A (ru) Химерные антигенные рецепторы со встроенными контролируемыми функциями
RU2020109577A (ru) Клетка
Kwong et al. Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity
JP2022527162A5 (cg-RX-API-DMAC7.html)
US12534509B2 (en) Engineered immune cells with receptor cross-talk
CN115348869A (zh) 细胞
NO313883B1 (no) Löselig fusjonsmolekyl og rekombinant fusjonsmolekyl som har bindingsspesifisitet for CD11a/CD18
JP2025524457A (ja) 哺乳動物におけるキメラ抗原受容体介在性の免疫応答を刺激するための方法において使用するためのcd123に対する標的化モジュール
TH1801006163A (th) ไคเมอริกรีเซพเตอร์ให้แก่ flt3 และวิธีการใช้สิ่งดังกล่าว